The GLP-1 Effect on Workers Comp: Obesity Is Finally Falling
NCCI's Paul Hendrick called it in one sentence: GLP-1 drugs are bringing obesity rates down. For a line of insurance where obesity is the costliest comorbidity, that's not a health story. It's a pricing story.
GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) are driving the first sustained decline in US adult obesity in decades, with 7.6 million fewer obese adults since 2022 (Gallup, 2025). Because obesity is a documented severity multiplier in workers compensation claims, particularly for falls and musculoskeletal injuries common in construction, a population-level obesity decline could meaningfully bend the workers comp severity curve over time.
Paul Hendrick, Practice Leader and Senior Actuary at NCCI (the National Council on Compensation Insurance), slipped in a line worth tracking at the 2025 Annual Insights Symposium. "Thanks to GLP-1s, obesity rates have declined," he said. "That's important because with obesity comes a higher likelihood of injury and slower recovery."
One sentence in a broader talk about aging workers. For anyone tracking where workers comp claim severity actually comes from, it was the most forward-looking remark of the day.
GLP-1 (glucagon-like peptide-1) receptor agonists are the drug class behind Ozempic, Wegovy, Zepbound, and Mounjaro. Originally developed for Type 2 diabetes management, they've become the first pharmaceutical intervention to produce a measurable, population-level decline in US obesity.
Obesity's Footprint on Workers Comp Claim Costs
The link between obesity and workers comp costs isn't new. A Duke Medical Center analysis found that obese employees filed twice the number of workers compensation claims as non-obese counterparts, with medical costs seven times higher and 13 times more workdays lost to injury (Duke Medical Center, 2007). That last number is worth sitting with. Thirteen times.
NCCI studied injuries across 40 states between 1998 and 2007, comparing 7,000 claims with an obesity comorbidity to over 20,000 similar claims without one. The findings: indemnity benefit duration at least five times greater for obese claimants. Among workers with severe injuries, obese claimants carried 3.19 times the odds of claim expenses exceeding $100,000 (NCCI, 2010).
In construction, the injury types that drive the highest severity (falls from elevation, back injuries, knee injuries) are the ones where obesity complicates recovery most. It doesn't cause the fall from the scaffold. It extends the surgical timeline, slows rehab, and inflates the reserve that sits on your worksheet.
GLP-1 Adoption and the Obesity Curve
For decades, US obesity data moved in one direction. Up. That changed.
Gallup's 2025 tracking shows the adult obesity rate fell from 39.9% in 2022 to 37.0%, a decline representing roughly 7.6 million fewer obese adults (Gallup, 2025). The driver isn't a fitness trend. It's pharmacology. Adults using GLP-1 drugs for weight loss more than doubled, from 5.8% in early 2024 to 12.4% in 2025.
The demographics matter for workers comp. The steepest obesity declines appeared in adults aged 50 to 64 (down 5.0 percentage points) and 40 to 49 (down 4.3 points). In workers comp, these are the age cohorts with the highest average claim severity. In construction, they're your most experienced field workers, the ones whose injuries tend to cost the most.
The Formulary Question Nobody Has Answered
GLP-1 drugs run $1,000 to $1,500 a month. In group health plans, employer coverage for weight management has expanded significantly over the past two years. In workers comp formularies, the question barely exists.
Enlyte's pharmacy data shows GLP-1 dispensing in workers comp grew 14.2% from 2021 to 2023, with a 13.2% increase in drug spend over the same period (Enlyte, 2024). But the compensability framework is narrow. A GLP-1 prescription typically must connect to the index injury itself, for instance, significant weight gain during prolonged post-injury immobility. Treating pre-existing obesity as a comorbidity to speed recovery from a work injury is a different legal question, and most state jurisdictions haven't touched it.
The arithmetic is suggestive. An annual drug cost of roughly $15,000 could pay for itself if it shortens a lost-time construction claim by even two or three weeks of indemnity. Workers comp doesn't reward that kind of forward-looking math. Not yet.
What This Means at Renewal
Don't expect your carrier to start covering Wegovy for your roofing crew. That's not where this is heading.
The signal is population-level. If GLP-1 adoption continues its current trajectory, the workforce your carrier prices five years from now will be lighter, on average, than the one it priced five years ago. That bends expected severity downward. Not overnight. Not uniformly across every classification code. But measurably, and in the direction that matters for your mod.
The nearer-term opportunity sits with return-to-work programs that address the whole worker, not just the index injury. We typically see the worst mod outcomes when claimants with comorbidities like obesity stall in recovery and reserves keep climbing. Anything that accelerates functional return, including GLP-1 access through group health when appropriate, has a downstream effect on the claim data your mod is calculated from.
What an Audit Would Check
An audit doesn't prescribe medications or design return-to-work protocols. It checks whether the claim data on your experience rating worksheet reflects how claims actually resolved. Obesity-related comorbidities tend to inflate reserves and stretch lost-time durations, and both feed directly into the mod formula. A reserve set high because a claimant's recovery was projected to be slow, when the actual outcome tracked faster, sits on your worksheet inflating your mod until someone corrects it.
Send us your NCCI worksheet and we'll review it at no cost.